IGNORED- your usefulness over. You lost your bung and now shorted. You just don't get it. Adios.
You have no belief in the company, no insight with you dumb reasoning that members here can't understand how complicated the brain is. Well many scientist don't even understand it just yet either. Maybe that's why all the Alzheimer's studies from the last 10 yrs have failed. There is now light at the end of the tunnel. Get on board or keep holding that short.
There may be some competition from ITCI( $26.96) and ACAD ($38.17) , both companies will be doing AD studies too. But AVXL is way ahead at this point a with 2-73 as a treatment and possible disease modifying. Not to mention the greatest potential for big gains with a ridiculously undervalued sp of $1.34.
Tangui Nicolas Maurice, Ph.D.
A member of the Scientific Advisory Board, Dr. Maurice has spent 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related disorders, and behavioral phenotyping of rodent models. Dr. Maurice is a researcher at the Institut national de la sante et de la recherche medicale (INSERM) U710 at Montpellier. He has also held research positions at the Centre National de la Recherche Scientifique (CNRS), INSERM U336, the department of neuropsychopharmacology and hospital pharmacy at Meijo University (Nagoya, Japan), and Jouveinal Research Institute (Fresnes, France).
I would doubt they can produce the drug and sell it on-line, esp with AVXL holding the patent. Looks a little shady so I am thinking that structure they show may not be correct.
It is our pleasure to welcome you to the Dementia Conferences 2015 during August 31 - September 02, 2015 Toronto, Canada. The conference will be organized around the theme of “Diagnosis Approaches of Dementia and Alzheimer’s Disease”.....Dementia, including Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million.....Today, over 35 million people worldwide currently live with the condition...... No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people.....In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.
Track 1: Causes and Prevention of Alzheimer’s...In this track we can discuss on Neurological changes in brain, Epidemiology and prevalence, Amyloid protein, Genetic associations and susceptibility genes, Role of Apolipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Histone modification, DNA methylation, Alzheimer’s disease prevention......many Renowned Speakers.
Between Over bought and Over sold, both stochastic and W%R in mid range. One thing is the MFI way down, looks like it is turning upward now. BB still fairly wide, but narrowing. Over all looks good, if MFI continues higher the sp will start to move higher.
Believe as you please about what the chart " says', I will go by what you say to judge your intentions.
" Alzheimers is too complicated, if not impossible, to cure with a silly pill."
many already staying away, sp not moving lower to their satisfaction. Chatter reflects some who shorted recently covering for only a few pennies. Those that bash know they don't have a clue why this stock has not fallen back to 50 cents like all the other pump and dumb stocks they shorted in the past.
Not worried...many catalyst not far off. Oct? In June 2015, the Company completed enrollment of 450 patients in the ITI-007-301 Phase 3 clinical trial in schizophrenia. Clinical conduct for this study has been completed. The Company expects topline results from this trial late in the third quarter or early in the fourth quarter of this year.
The best "gift" I ever got from a detail guy was 3days 2 nights at the La Costa Resort and Spa near San Diego, and all i had to do was listen to a 1+hour lecture on Capoten.